Paraneoplastic glomerular diseases and malignancies

被引:148
|
作者
Bacchetta, Justine [1 ]
Juillard, Laurent [2 ]
Cochat, Pierre [1 ]
Droz, Jean-Pierre [3 ]
机构
[1] Hop Femme Mere Enfant, Reference Ctr Rare Renla Dis, F-69600 Bron, France
[2] Univ Lyon 1, Hop Edouard Herriot, Dept Nephrol, F-69003 Lyon, France
[3] Univ Lyon 1, Ctr Leon Berard, Dept Med Oncol, F-69003 Lyon, France
关键词
Paraneoplastic glomerular disease; Nephrotic syndrome; Cancer; Membranous nephropathy; Carcinoma; RENAL-CELL-CARCINOMA; CHANGE NEPHROTIC SYNDROME; MINIMAL-CHANGE NEPHROPATHY; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; HENOCH-SCHONLEIN PURPURA; ANTINEUTROPHIL CYTOPLASMIC ANTIBODY; ENDOTHELIAL GROWTH-FACTOR; LONG-TERM PROGNOSIS; OF-THE-LITERATURE;
D O I
10.1016/j.critrevonc.2008.08.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Paraneoplastic glomerulopathies are rare manifestations of neoplastic disease to be distinguished from iatrogenic renal damage. Solid tumors are preferentially associated with membranous nephropathy, whereas Hodgkin's lymphomas are associated with minimal change disease. The most common neoplasia associated with paraneoplastic glomerular disease are carcinomas of the lung and of the gastrointestinal tract. Nephrotic syndrome is the most frequent presentation of paraneoplastic glomerulopathy and the most critical glomerular disease regarding prognosis and patient care. Renal biopsy is recommended in patients with glomerular proteinuria or nephrotic syndrome and cancer, depending on life expectancy and therapeutic options. The primary treatment must be directed at the cancer in all cases. Symptomatic treatment of the nephrotic syndrome with diuretics and ACE inhibitors is justified. Prevention of nephrotic syndrome complications, i.e. thromboses and infections, should also be addressed and systematic regular renal follow-up is warranted. All treatments should be regularly reviewed to avoid toxicity, associated renal function loss or low albumin levels for patients receiving albumin-binding drugs. Epidemiologic studies have low evidence-based value. There is no widely accepted experimental model of the association of glomerulopathy and cancer. Thus, epidemiologic and mechanistic studies are needed to determine the true prevalence of paraneoplastic glomerulopathies and investigate new pathophysiologic approaches. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:39 / 58
页数:20
相关论文
共 50 条
  • [31] Paraneoplastic alopecia associated with internal malignancies in the cat
    PascalTenorio, A
    Olivry, T
    Gross, TL
    Atlee, BA
    Ihrke, PJ
    VETERINARY DERMATOLOGY, 1997, 8 (01) : 47 - 52
  • [32] Paraneoplastic syndromes and rheumatic diseases
    Swierkot, Jerzy
    Lewandowicz-Uszynska, Aleksandra
    Bogunia-Kubik, Katarzyna
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2014, 68 : 944 - 954
  • [33] Glomerular Diseases Across Lifespan: Key Differences in Diagnostic and Therapeutic Approaches
    Windpessl, Martin
    Odler, Balazs
    Bajema, Ingeborg M.
    Geetha, Duvuru
    Saemann, Marcus
    Lee, Jiwon M.
    Vaglio, Augusto
    Kronbichler, Andreas
    SEMINARS IN NEPHROLOGY, 2023, 43 (04)
  • [34] Treatment of Resistant Glomerular Diseases with Adrenocorticotropic Hormone Gel: A Prospective Trial
    Bomback, Andrew S.
    Canetta, Pietro A.
    Beck, Laurence H., Jr.
    Ayalon, Rivka
    Radhakrishnan, Jai
    Appel, Gerald B.
    AMERICAN JOURNAL OF NEPHROLOGY, 2012, 36 (01) : 58 - 67
  • [35] Epidemiology and Outcomes of Glomerular Diseases in Low- and Middle-Income Countries
    Ekrikpo, Udeme
    Obiagwu, Patience
    Chika-Onu, Ugochi
    Yadla, Manjusha
    Karam, Sabine
    Tannor, Elliot K.
    Bello, Aminu K.
    Okpechi, Ikechi G.
    SEMINARS IN NEPHROLOGY, 2022, 42 (05)
  • [36] A novel dosing approach for rituximab in glomerular diseases based on a population pharmacokinetic analysis
    Hartinger, Jan Miroslav
    Sima, Martin
    Hruskova, Zdenka
    Pilkova, Alena
    Kratky, Vojtech
    Rysava, Romana
    Jancova, Eva
    Bobek, Daniel
    Dousa, Jiri
    Francova, Ivana
    Tesar, Vladimir
    Slanar, Ondrej
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 175
  • [37] An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases
    Appel, Alice S.
    Appel, Gerald B.
    NATURE CLINICAL PRACTICE NEPHROLOGY, 2009, 5 (03): : 132 - 142
  • [38] Complement and Complement Targeting Therapies in Glomerular Diseases
    Andrighetto, Sofia
    Leventhal, Jeremy
    Zaza, Gianluigi
    Cravedi, Paolo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (24)
  • [39] Glomerular Diseases Associated With Hepatitis B and C
    Gupta, Anu
    Quigg, Richard J.
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2015, 22 (05) : 343 - 351
  • [40] CYCLOSPORINE IN THE TREATMENT OF GLOMERULAR-DISEASES IN CHILDREN
    BRODEHL, J
    HOYER, PF
    EHRICH, JHH
    BOKENKAMP, A
    NIEREN-UND HOCHDRUCKKRANKHEITEN, 1993, 22 : S31 - S39